Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Nakamuta

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Journal of Gastroenterology and Hepatology|February 24, 2001
Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic responseM Nakamuta, T Fukutomi, N Shimohashi, et al.
Alimentary Pharmacology & Therapeutics|October 17, 2017
Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatmentE Ogawa, N Furusyo, H Nomura, et al.
Journal of Gastroenterology and Hepatology|February 24, 2001
Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphomaM Kuniyoshi, M Nakamuta, H Sakai, et al.
Journal of Medical Virology|March 18, 2011
Expression profiles of genes associated with viral entry in HCV-infected human liverM Nakamuta, T Fujino, R Yada, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2009
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathwayM Nakamuta, T Fujino, R Yada, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Journal of Gastroenterology and Hepatology|February 24, 2001
Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic responseM Nakamuta, T Fukutomi, N Shimohashi, et al.
Alimentary Pharmacology & Therapeutics|October 17, 2017
Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatmentE Ogawa, N Furusyo, H Nomura, et al.
Journal of Gastroenterology and Hepatology|February 24, 2001
Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphomaM Kuniyoshi, M Nakamuta, H Sakai, et al.
Journal of Medical Virology|March 18, 2011
Expression profiles of genes associated with viral entry in HCV-infected human liverM Nakamuta, T Fujino, R Yada, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2009
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathwayM Nakamuta, T Fujino, R Yada, et al.
Pageof 7